Your browser doesn't support javascript.
loading
Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis.
Zhuang, Liwei; Li, Junnan; Zhang, Yu; Ji, Shibo; Li, Yue; Zhao, Yingying; Li, Ben; Li, Wei; Quan, Min; Duan, Ying; Zhao, Hong; Cheng, Danying; Wang, Xiaomei; Ou, Weini; Xing, Huichun.
Afiliação
  • Zhuang L; Center of Liver Disease Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China; Peking University Ditan Teaching Hospital, Beijing, China.
  • Li J; Department of Science and Education, Beijing Ditan Hospital, Capital Medical University, Beijing, China; Peking University Ditan Teaching Hospital, Beijing, China.
  • Zhang Y; Center of Liver Disease Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Ji S; Center of Liver Disease Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Li Y; Center of Liver Disease Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Zhao Y; Center of Liver Disease Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Li B; Center of Liver Disease Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Li W; Center of Liver Disease Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Quan M; Center of Liver Disease Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Duan Y; Center of Liver Disease Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Zhao H; Center of Liver Disease Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Cheng D; Center of Liver Disease Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Wang X; Center of Liver Disease Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China; Peking University Ditan Teaching Hospital, Beijing, China.
  • Ou W; Center of Liver Disease Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China; Peking University Ditan Teaching Hospital, Beijing, China.
  • Xing H; Center of Liver Disease Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China; Peking University Ditan Teaching Hospital, Beijing, China. Electronic address: hchxing@sohu.com.
Ann Hepatol ; 23: 100268, 2021.
Article em En | MEDLINE | ID: mdl-33059055
Patients with hepatitis C virus (HCV) genotype 3 (GT3) infection are resistant to direct-acting antiviral (DAA) treatments. This study aimed to analyze the effectiveness of sofosbuvir (SOF)+daclatasvir (DCV) ± ribavirin (RBV); SOF+velpatasvir (VEL)±RBV; SOF+VEL+voxilaprevir (VOX); and glecaprevir (GLE)+pibrentasvir (PIB) in the treatment of HCV GT3-infected patients in real-world studies. Articles were identified by searching the PubMed, EMBASE, and Cochrane Library databases from January 1, 2016 to September 10, 2019. The meta-analysis was conducted to determine the sustained virologic response (SVR) rate, using R 3.6.2 software. Thirty-four studies, conducted on a total of 7328 patients from 22 countries, met the inclusion criteria. The pooled SVR rate after 12/24 weeks of treatment was 92.07% (95% CI: 90.39-93.61%) for the evaluated regimens. Also, the SVR rate was 91.17% (95% CI: 89.23-92.94%) in patients treated with SOF+DCV±RBV; 95.08% (95% CI: 90.88-98.13%) in patients treated with SOF+VEL±RBV; 84.97% (95% CI: 73.32-93.91%) in patients treated with SOF+VEL+VOX; and 98.54% (95% CI: 96.40-99.82%) in patients treated with GLE+PIB. The pooled SVR rate of the four regimens was 95.24% (95% CI: 93.50-96.75%) in non-cirrhotic patients and 89.39% (95% CI: 86.07-92.33%) in cirrhotic patients. The pooled SVR rate was 94.41% (95% CI: 92.02-96.42%) in treatment-naive patients and 87.98% (95% CI: 84.31-91.25%) in treatment-experienced patients. The SVR rate of GLE+PIB was higher than other regimens. SOF+VEL+VOX can be used as a treatment regimen following DAA treatment failure.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Pirrolidinas / Quinoxalinas / Sulfonamidas / Valina / Benzimidazóis / Carbamatos / Hepatite C / Compostos Macrocíclicos / Sofosbuvir Tipo de estudo: Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Ann Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China País de publicação: México
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Pirrolidinas / Quinoxalinas / Sulfonamidas / Valina / Benzimidazóis / Carbamatos / Hepatite C / Compostos Macrocíclicos / Sofosbuvir Tipo de estudo: Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Ann Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China País de publicação: México